Have a personal or library account? Click to login
CREBBP is a Major Prognostic Biomarker for Relapse in Childhood B-cell Acute Lymphoblastic Leukemia: A National Study of Unselected Cohort Cover

CREBBP is a Major Prognostic Biomarker for Relapse in Childhood B-cell Acute Lymphoblastic Leukemia: A National Study of Unselected Cohort

Balkan Journal of Medical Genetics
Volume 27 (2024): Issue 2 (December 2024)
By:
Open Access
|Mar 2025

References

  1. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)-NCI. Available online: https://www.cancer. gov/types/leukemia/hp/child-all-treatment-pdq (accessed on 16.10.2024).
    Search in Google ScholarBack to article
  2. SEER*Explorer Application. Available online: https://seer.cancer.gov/statistics-network/explorer/application.html?site=92&data_type=1&graph_ type=1&compareBy=sex&chk_sex_1=1&rate_ type=2&race=1&age_range=16&advopt_ precision=1&advopt_show_ci=on&hdn_ view=0&advopt_show_apc=on&advopt_ display=2#resultsRegion0 (accessed on 16.10.2024)
    Search in Google ScholarBack to article
  3. Forero RM, Hernández M, Hernández-Rivas JM. Genetics of Acute Lymphoblastic Leukemia. In <em>Leukemia</em>. Prof. Margarita Guenova (Ed.); IntechOpen: London, UK, 2013; doi:<a href="https://doi.org/10.5772/55504" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.5772/55504</a>
    Open DOISearch in Google ScholarBack to article
  4. Studd JB, Cornish AJ, Hoang PH, Law P, Kinnersley B, Houlston R. Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes. <em>Blood Cancer J</em>. <bold>2021</bold>;<em>11(11):</em>1-10. doi:<a href="https://doi.org/10.1038/s41408-021-00570-9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s41408-021-00570-9</a>
    Open DOISearch in Google ScholarBack to article
  5. Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. <em>Hematology</em>. <bold>2012</bold>;<em>2012(1):</em>389-396. doi:<a href="https://doi.org/10.1182/asheducation.V2012.1.389.3798360" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1182/asheducation.V2012.1.389.3798360</a>
    Open DOISearch in Google ScholarBack to article
  6. Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. <em>Blood</em>. <bold>2015</bold>;<em>125(26)</em>:3977-3987. doi:<a href="https://doi.org/10.1182/blood-2015-02-580043" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1182/blood-2015-02-580043</a>
    Open DOISearch in Google ScholarBack to article
  7. Woo JS, Alberti MO, Tirado CA. Childhood B-acute lymphoblastic leukemia: a genetic update. <em>Exp. hema-tol. oncol</em>. <bold>2014</bold>;<em>3(1):</em>16. doi:<a href="https://doi.org/10.1186/2162-3619-3-16" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/2162-3619-3-16</a>
    Open DOISearch in Google ScholarBack to article
  8. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. <em>The Lancet</em>. <bold>2013</bold>;<em>381(9881):</em>1943-1955. doi:<a href="https://doi.org/10.1016/S0140-6736(12)62187-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S0140-6736(12)62187-4</a>
    Open DOISearch in Google ScholarBack to article
  9. Rob Pieters, Charles G. Mullighan, Stephen P. Hunger. Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL. <em>J. Clin. Oncol</em>. <bold>2023</bold>;<em>41</em>:5579-5591. doi:<a href="https://doi.org/10.1200/JCO.23.01286" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.23.01286</a>
    Open DOISearch in Google ScholarBack to article
  10. Chang TC, Chen W, Qu C, et al. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. <em>J. Clin. Oncol</em>. <bold>2024</bold>;<em>42(29):</em>3491-3503. doi:<a href="https://doi.org/10.1200/JCO.23.02238" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.23.02238</a>
    Open DOISearch in Google ScholarBack to article
  11. Brady SW, Roberts KG, Gu Z, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. <em>Nat Genet</em>. <bold>2022</bold>;<em>54(9):</em>1376-1389. doi:<a href="https://doi.org/10.1038/s41588-022-01159-z" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s41588-022-01159-z</a>
    Open DOISearch in Google ScholarBack to article
  12. Morscio J, Van Vlierberghe P. Chemotherapy at the wheel of ALL relapse. <em>Blood</em>. <bold>2020</bold>;<em>135(1):</em>4-5. doi:<a href="https://doi.org/10.1182/blood.2019003870" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1182/blood.2019003870</a>
    Open DOISearch in Google ScholarBack to article
  13. Mullighan CG, Phillips LA, Su X, et al. Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia. <em>Science</em>. <bold>2008</bold>;<em>322(5906):</em>1377-1380. doi:<a href="https://doi.org/10.1126/science.1164266" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1126/science.1164266</a>
    Open DOISearch in Google ScholarBack to article
  14. Zhang H, Wang H, Qian X, et al. Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing. <em>BMC Cancer</em>. <bold>2020</bold>;<em>20(1):</em>211. doi:<a href="https://doi.org/10.1186/s12885-020-6709-7" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/s12885-020-6709-7</a>
    Open DOISearch in Google ScholarBack to article
  15. Ueno H, Yoshida K, Shiozawa Y, et al. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. <em>Blood Adv</em>. <bold>2020</bold>;<em>4(20):</em>5165. doi:<a href="https://doi.org/10.1182/bloodad-vances.2019001307" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1182/bloodad-vances.2019001307</a>
    Open DOISearch in Google ScholarBack to article
  16. van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. <em>Leukemia</em>. <bold>2003</bold>;<em>17(12):</em>2257-2317. doi:<a href="https://doi.org/10.1038/sj.leu.2403202" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/sj.leu.2403202</a>
    Open DOISearch in Google ScholarBack to article
  17. Krstevska Bozhinovikj E, Matevska-Geshkovska N, Stojovska M, et al. Presence of Minimal Residual Disease Determined by Next-Generation Sequencing Is Not a Reliable Prognostic Biomarker in Children with Acute Lymphoblastic Leukemia. <em>Leuk Lymphoma</em> 2024 <em>(submitted)</em> doi:<a href="https://doi.org/10.22541/au.172536128.83797266/v1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.22541/au.172536128.83797266/v1</a>
    Open DOISearch in Google ScholarBack to article
  18. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. <em>Leukemia</em>. <bold>1999</bold>;<em>13(12):</em>1901-1928. doi:<a href="https://doi.org/10.1038/sj.leu.240159" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/sj.leu.240159</a>
    Open DOISearch in Google ScholarBack to article
  19. ALL IC-BFM 2009 A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia; Available online: https://ascopubs.org/doi/suppl/10.1200/JCO.22.01760/suppl_file/protocol1_jco.22.01760.pdf (accessed 16.10.2024)
    Search in Google ScholarBack to article
  20. Stanulla M, Dagdan E, Zaliova M, et al. IKZF1p-lus Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. <em>J. Clin. Oncol</em>. <bold>2018</bold>;<em>36(12)</em>:1240-1249. doi:<a href="https://doi.org/10.1200/JCO.2017.74.3617" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2017.74.3617</a>
    Open DOISearch in Google ScholarBack to article
  21. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? <em>Blood</em>. <bold>2012</bold>;<em>120(6)</em>:1165-1174. doi:<a href="https://doi.org/10.1182/blood-2012-05-378943" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1182/blood-2012-05-378943</a>
    Open DOISearch in Google ScholarBack to article
  22. Li B, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. <em>Blood</em>. <bold>2020</bold>;<em>135(1):</em>41-55. doi:<a href="https://doi.org/10.1182/blood.2019002220" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1182/blood.2019002220</a>
    Open DOISearch in Google ScholarBack to article
  23. Oshima K, Khiabanian H, da Silva-Almeida AC, et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. <em>Proc Natl Acad Sci U S A</em>. <bold>2016</bold>;<em>113(40):</em>11306-11311. doi:<a href="https://doi.org/10.1073/pnas.1608420113" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1073/pnas.1608420113</a>
    Open DOISearch in Google ScholarBack to article
  24. Sayyab S, Lundmark A, Larsson M, et al. Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia. <em>Sci Rep</em>. <bold>2021</bold>;<em>11(1):</em>15988. doi:<a href="https://doi.org/10.1038/s41598-021-95109-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s41598-021-95109-0</a>
    Open DOISearch in Google ScholarBack to article
  25. Malinowska-Ozdowy K, Frech C, Schönegger A, et al. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. <em>Leukemia</em>. <bold>2015</bold>;<em>29(8):</em>1656-1667. doi:<a href="https://doi.org/10.1038/leu.2015.107" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/leu.2015.107</a>
    Open DOISearch in Google ScholarBack to article
  26. Zhu Y, Wang Z, Li Y, et al. The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies. <em>Cancers</em>. <bold>2023</bold>;<em>15(4):</em>1219. doi:<a href="https://doi.org/10.3390/cancers15041219" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/cancers15041219</a>
    Open DOISearch in Google ScholarBack to article
  27. Ramírez-Komo JA, Delaney MA, Straign D, et al. Spontaneous loss of B lineage transcription factors leads to pre-B leukemia in Ebf1+/–Bcl-xLTg mice. <em>Oncogenesis</em>. <bold>2017</bold>;<em>6(7):</em>e355-e355. doi:<a href="https://doi.org/10.1038/oncsis.2017.55" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/oncsis.2017.55</a>
    Open DOISearch in Google ScholarBack to article
  28. Yang JJ, Bhojwani D, Yang W, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. <em>Blood</em>. <bold>2008</bold>;<em>112(10):</em>4178-4183. doi:<a href="https://doi.org/10.1182/blood-2008-06-165027" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1182/blood-2008-06-165027</a>
    Open DOISearch in Google ScholarBack to article
  29. Li X, Lin S, Liao N, et al. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children’s leukemia group. <em>Hematol. Oncol</em>. <bold>2024</bold>;<em>42(3):</em>e3265. doi:<a href="https://doi.org/10.1002/hon.3265" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/hon.3265</a>
    Open DOISearch in Google ScholarBack to article
  30. Park KJ, Kim IS. Clinically actionable mutations identified in Korean patients with high-risk acute lymphoblastic leukemia. <em>Ann Oncol</em>. <bold>2018</bold>;<em>29</em>:viii370-viii371. doi:<a href="https://doi.org/10.1093/annonc/mdy286.036" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdy286.036</a>
    Open DOISearch in Google ScholarBack to article
  31. Vervoort BMT, Butler M, Grünewald KJT, et al. IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia. <em>Haematologica</em>. Published online June 6, <bold>2024</bold>. doi:<a href="https://doi.org/10.3324/haematol.2023.284357" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3324/haematol.2023.284357</a>
    Open DOISearch in Google ScholarBack to article
  32. Stanulla M, Cavé H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? <em>Blood</em>. <bold>2020</bold>;<em>135(4):</em>252-260. doi:<a href="https://doi.org/10.1182/blood.2019000813" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1182/blood.2019000813</a>
    Open DOISearch in Google ScholarBack to article
  33. Feng J, Guo Y, Yang W, et al. Childhood Acute B-Lineage Lymphoblastic Leukemia With CDKN2A/B Deletion Is a Distinct Entity With Adverse Genetic Features and Poor Clinical Outcomes. <em>Front Oncol</em>. <bold>2022</bold>;<em>12</em>. doi:<a href="https://doi.org/10.3389/fonc.2022.878098" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3389/fonc.2022.878098</a>
    Open DOISearch in Google ScholarBack to article
  34. Ampatzidou M, Papadhimitriou SI, Paisiou A, et al. The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols. <em>Diagnostics</em>. <bold>2023</bold>;<em>13(9):</em>1589. doi:<a href="https://doi.org/10.3390/diagnostics13091589" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/diagnostics13091589</a>
    Open DOISearch in Google ScholarBack to article
  35. Oshima K, Zhao J, Pérez-Durán P, et al. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. <em>Nat Cancer</em>. <bold>2020</bold>;<em>1(11):</em>1113-1127. doi:<a href="https://doi.org/10.1038/s43018-020-00124-1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s43018-020-00124-1</a>
    Open DOISearch in Google ScholarBack to article
DOI: https://doi.org/10.2478/bjmg-2024-0020 | Journal eISSN: 2199-5761
Journal RSS Feed
Language: English
Page range: 5 - 12
Published on: Mar 6, 2025
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
acute lymphoblastic leukemia,
relapse,
molecular biomarkers
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2025 E Krstevska Bozhinovikj, N Matevska-Geshkovska, M Staninova Stojovska, E Gjorgievska, A Jovanovska, S Kocheva, A Dimovski, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 27 (2024): Issue 2 (December 2024)Next article